Rare Diseases and Orphan Drugs

The regulatory considerations for the orphan drugs is a processes the FDA has the authority to grant orphan drug designation to a biological product or drug to prevent or o treat the disease or condition. The orphan drugs are the drugs intended for the use of a rare disease or condition that is defined as section 526 of the act.

Submit Abstract Now